NCT03674593

Brief Summary

The study compares the efficacies of two surgical procedures for the treatment of mitral valve prolapse due to myxomatous degeneration of the mitral valve: the chordae replacement and the translocation of secondary mitral valve chordae.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
64

participants targeted

Target at P50-P75 for not_applicable

Timeline
8mo left

Started Jul 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress92%
Jul 2018Dec 2026

First Submitted

Initial submission to the registry

July 9, 2018

Completed
Same day until next milestone

Study Start

First participant enrolled

July 9, 2018

Completed
2 months until next milestone

First Posted

Study publicly available on registry

September 17, 2018

Completed
7.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Expected
Last Updated

April 9, 2025

Status Verified

April 1, 2025

Enrollment Period

7.5 years

First QC Date

July 9, 2018

Last Update Submit

April 7, 2025

Conditions

Keywords

Mitral Valve ChordaeDegenerative Mitral Valve DiseaseMitral Valve Chordae ReplacementMitral Valve Chordae TranslocationMitral Valve Chordae Prosthetics

Outcome Measures

Primary Outcomes (1)

  • Mitral regurgitation degree measure

    Mitral regurgitation degree (from 1 to 4) assessed by echocardiography two weeks after surgery

    Two weeks

Secondary Outcomes (2)

  • Surgical efficacy measure

    One year

  • ERO measure

    Two weeks

Study Arms (2)

Mitral valve chordae prosthesis

EXPERIMENTAL

Patients of this group receive mitral valve chordae replacement performed in five stages: 1. Measure the required length of the chordae. 2. Forming loops. 3. Fixation of the loop group to the papillary muscles. 4. Fixation of chordal loops to the free edge of the valve. 5. Annuloplasty with a support ring and a hydraulic test to confirm the absence of prolapse.

Procedure: Mitral valve chordae prosthesis

Mitral valve chordae translocation

ACTIVE COMPARATOR

The technique of translocation of secondary chordae: The method consists essentially of three stages: 1. Selection of the secondary chordae. 2. Fixation of secondary chordae to the free edge of the valve. 3. Annuloplasty support ring and hydraulic test to confirm the absence of prolapse.

Procedure: Mitral valve chordae translocation

Interventions

The method consists of five stages: 1. Measure the required length of the chords 2. Forming loops 3. Fixation of the loop group to the papillary muscles 4. Fixation of chordal loops to the free edge of the valve 5. Annuloplasty with a support ring and a hydraulic test to confirm the absence of prolapse

Also known as: Chordae prosthesis
Mitral valve chordae prosthesis

The method consists essentially of three stages: 1. Selection of the secondary chord. 2. Fixation of secondary chords to the free edge of the valve. 3. Annuloplasty support ring and hydraulic test to confirm the absence of prolapse.

Also known as: Chordae translocation
Mitral valve chordae translocation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Isolated type II mitral valve insufficiency by A. Carpentier
  • Mitral regurgitation degree \>2
  • Age \>18 years
  • Signed informed consent to participate in the study

You may not qualify if:

  • Any other cardiac surgeries
  • Age \<18 years
  • Multiple organ failure
  • ReDo procedure
  • Persistent atrial fibrillation
  • Acute infective endocarditis
  • Refusal to sign informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cardiology Research Institute, Tomsk NRMC

Tomsk, 634012, Russia

Location

Study Officials

  • Elena N. Pavlyukova, MD, PhD

    Tomsk NRMC

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
Single blind masking (Participant)
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Single-center, prospective, semi-open, randomized study
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 9, 2018

First Posted

September 17, 2018

Study Start

July 9, 2018

Primary Completion

December 31, 2025

Study Completion (Estimated)

December 31, 2026

Last Updated

April 9, 2025

Record last verified: 2025-04

Data Sharing

IPD Sharing
Will not share

Locations